Inivata in the News
Inivata has been in the news a lot recently! Please see below two events which have prompted this coverage:
- We have been nominated for the BioNewsAward 2016 from OneNucleus based on our Series A press release and what we are doing with these funds (there is a slide presentation under the Inivata link): http://www.genesisconference.com/pre-genesis-seminar–bionewsround-2016-award/
- We have been named one of the Top 5 European Bio Tech Startups to watch by StartUs magazine: http://magazine.startus.cc/top-5-european-biotech-startups/
Have a look at these news stories if you can and share our excitement. We have great things in store for changing cancer care and treatment.
About Inivata
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts
Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson
Paul Rabin (US)
inivata@consilium-comms.com +44 (0)20 3709 5700, +1 516 503 0271
Karen Chandler-Smith
karen.chandler-smith@inivata.com +44 (0)7900 430235
